BrightGene Bio Medical Technology C (688166) — Net Asset Quality Index
BrightGene Bio Medical Technology C (688166) has a Net Asset Quality Index of 48.0% as of June 2025. This metric measures the proportion of total assets financed by shareholders' equity — total assets of CN¥5.38 Billion minus total liabilities of CN¥2.80 Billion yields net assets of CN¥2.59 Billion. A higher index indicates a stronger, lower-leverage balance sheet. Check 688166 financial resilience to evaluate the company's liquid asset resilience ratio.
Quality Index
Net Assets
Total Assets
Total Liabilities
BrightGene Bio Medical Technology C Net Asset Quality Index Over Time (2016–2024)
This chart shows how BrightGene Bio Medical Technology C's Net Asset Quality Index has evolved across 9 annual periods from 2016 to 2024. As of June 2025, the index stands at 48.0%, representing net assets of CN¥2.59 Billion against total assets of CN¥5.38 Billion CNY. See BrightGene Bio Medical Technology C (688166) liquidity to equity ratio to evaluate short-term liquidity relative to the company's equity base.
Annual Net Asset Quality Index for BrightGene Bio Medical Technology C (2016–2024)
The table below presents the year-by-year Net Asset Quality Index for BrightGene Bio Medical Technology C from 2016 to 2024, covering 9 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see 688166 market cap.
| Year | Quality Index | Net Assets (CNY) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2024 | 47.2% | CN¥2.44 Billion | CN¥5.16 Billion | CN¥2.73 Billion | ▼ -0.8 pp |
| 2023 | 48.0% | CN¥2.42 Billion | CN¥5.03 Billion | CN¥2.61 Billion | ▼ 0.0 pp |
| 2022 | 48.1% | CN¥2.24 Billion | CN¥4.66 Billion | CN¥2.42 Billion | ▼ -10.6 pp |
| 2021 | 58.6% | CN¥1.74 Billion | CN¥2.97 Billion | CN¥1.23 Billion | ▼ -19.7 pp |
| 2020 | 78.4% | CN¥1.43 Billion | CN¥1.83 Billion | CN¥395.23 Million | ▼ -14.0 pp |
| 2019 | 92.4% | CN¥1.31 Billion | CN¥1.42 Billion | CN¥108.21 Million | ▲ +4.4 pp |
| 2018 | 88.0% | CN¥772.85 Million | CN¥878.37 Million | CN¥105.52 Million | ▲ +3.0 pp |
| 2017 | 85.0% | CN¥446.02 Million | CN¥524.92 Million | CN¥78.89 Million | ▲ +27.7 pp |
| 2016 | 57.3% | CN¥220.15 Million | CN¥384.19 Million | CN¥164.05 Million | — |